Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Heather R Brodkin

2PUBLICATIONS

17CO-AUTHORS

TransgenesisApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (2)

Sort by Publication Date:

|Feb 13, 2026

WTX-124, a Conditionally Activated Wild-Type IL2, Maximizes the Therapeutic Index of IL2, Unlike "Non-Alpha" Muteins.

Christopher J Nirschl, Kulandayan K Subramanian, Heather R Brodkin

|Apr 19, 2023

mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity.

Christopher J Nirschl, Heather R Brodkin, Celesztina Domonkos

Pageof 1

Frequent Collaborators

2 joint publications

Christopher J Nirschl

2 joint publications

Celesztina Domonkos

2 joint publications

Connor J Dwyer

2 joint publications

Daniel J Hicklin

2 joint publications

Nesreen S Ismail

2 joint publications

Cynthia Seidel-Dugan

2 joint publications

Zoe Steuert

2 joint publications

Jenna M Sullivan

2 joint publications

William M Winston

2 joint publications

Andres Salmeron

Frequent Collaborators

2 joint publications

Christopher J Nirschl

2 joint publications

Celesztina Domonkos

2 joint publications

Connor J Dwyer

2 joint publications

Daniel J Hicklin

Top Related Videos

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on : Jan 15, 2011

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on : Feb 24, 2023

See more related videos

Top Related Videos

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

<em>Ex vivo</em> Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on : Jan 15, 2011

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on : Feb 24, 2023

See more related videos